gsk posts
FeedPosted Jan 15th 2011 10:30AM by Ted Allrich (RSS feed)
Filed under: Apple Inc (AAPL), Cisco Systems (CSCO), Intel (INTC), Ford Motor (F), General Motors (GM), International Business Machines (IBM), Procter and Gamble (PG), duPont(E.I.)deNemours (DD), Comfort Zone Investing
Economies go in cycles. They push to their breaking points, then move in the opposite direction. We saw it clearly in the '90s when there was no end to up (except there was and we abruptly hit it in 2000). In 2008, it felt like there was no end to down. But we now know there is. Things are picking up, and there are numbers to prove it.
Don't be the last to figure out we're in an economic recovery. Sitting on the sidelines, waiting for one more chance to buy a stock at the bargain price you saw in March of 2009 isn't going to happen. Times have changed. The U.S. economy is on the mend.
Continue reading Comfort Zone Investing: Can You Feel the Pendulum Swinging?
Posted Jan 11th 2011 11:00AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Hewlett-Packard (HPQ), Advanced Micro Dev (AMD), Alcoa Inc (AA), CIT Group (CIT), AMR Corp (AMR), Analyst Initiations
Analyst Upgrades
- Hewlett-Packard (HPQ) to buy from neutral at UBS.
- Fluor (FLR) to overweight from neutral at JPMorgan.
- Macy's (M) to outperform from neutral at Credit Suisse.
- Canadian Solar (CSIQ), JA Solar (JASO) and HeartWare (HTWR) to buy from hold at Auriga.
- Ashford Hospitality (AHT) to outperform from market perform at FBR Capital.
- RenaissanceRe (RNR) to buy from neutral at Janney Capital.
- DCT Industrial (DCT) to market perform from underperform at Wells Fargo.
- Coeur d'Alene Mines (CDE) and Silver Standard (SSRI) to buy from hold at Deutsche Bank.
- Weatherford (WFT), Hercules (HERO), GulfMark Offshore (GLF), Tidewater (TDW) and GlaxoSmithKline (GSK) to buy from hold, and Diamond Offshore (DO) to hold from underperform, at Jefferies.
- Ritchie Bros. (RBA) to buy from neutral at BofA/Merrill.
- AstraZeneca (AZN) to buy from hold at Citigroup.
Continue reading Analyst Calls: AA, AMD, AMR, AZN, CIT, GSK, HPQ, M, NVDA, PCX, SPWRA ...
Posted Nov 24th 2010 3:40PM by Gary Sattler (RSS feed)
Filed under: Deals, Products and Services, Pfizer (PFE), Lilly (Eli) (LLY)
Although short-term news may seem bright for Eli Lilly & Co. (LLY), the broader picture for the company looks flat. Having dropped from an average share price in the $53 range over two years ago, to a current average share value hovering near $35, investors are signaling that the long range forecast for Lilly is unexciting at best.
It appears that Lilly shall be buoyed in the near term by the recent FDA approval of testosterone replacement therapy Axiron for sale in the U.S. Lilly purchased rights to Axiron from Australian firm, Acrux for an initial payment of $50 million plus $3 million based on the transfer of manufacturing assets.
Continue reading Eli Lilly Likely to Remain Limp
Posted Sep 15th 2010 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, General Electric (GE), 3M Corporation (MMM), Nokia Corp. (NOK), Analyst Initiations
Analyst Upgrades
- Citigroup assumed coverage of Illinois Tool Works (ITW) and upgraded shares to buy from hold with a $52 price target. Citi cites valuation and the company's successful execution for the rating change.
- UBS upgraded Rowan Companies (RDC) to buy from neutral based on better-than-expected dayrates in the high specification jack-up market. The firm raised its price target to $42 from $28.
- UBS also upgraded NetLogic (NETL) to buy from neutral and keeps a $33.50 target on the stock. The firm upgraded shares based on valuation and solid long-term outlook.
- AvalonBay (AVB) and BRE Properties (BRE) were upgraded to neutral from underperform at Macquarie.
- Covance (CVD) was upgraded to equal weight from underweight at Morgan Stanley.
- Reynolds American (RAI) was upgraded to neutral from underperform at BofA/Merrill.
Continue reading Analyst Calls: BKS, GE, GSK, ITW, MMM, MXIM, NETL, NOK, RAI, RDC, TYC ...
Posted Sep 7th 2010 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Nokia Corp. (NOK), Campbell Soup (CPB), Analyst Initiations
Analyst Upgrades
- FBR Capital upgraded Pioneer Natural (PXD) to outperform from market perform and raised its price target for shares to $85 from $60. The firm upgraded shares on expectations that returns from the company's Spraberry field will increase materially.
- Baird upgraded Acroda Therapeutics (ACOR) to outperform from neutral based on valuation and a new survey that indicates a strong uptake for Ampyra and improvements on the reimbursement front. The firm has a $40 target on the stock.
- Morgan Stanley upgraded Nokia (NOK) to overweight from underweight based on checks that indicate strong orders and less than expected discounting for its upcoming N8 smartphone.
- GlaxoSmithKline (GSK) and British American Tobacco (BTI) were upgraded to buy from neutral at BofA/Merrill.
- Quality Systems (QSII) was upgraded to outperform from market perform at William Blair.
- Siemens (SI) was upgraded to buy from neutral at UBS.
Continue reading Analyst Calls: ACOR, CHKM, CPB, ENV, GDOT, GR, GSK, MFE, NOK, OXY, PXD, SI ...
Posted Jul 27th 2010 9:00AM by Paul Foster (RSS feed)
Filed under: Johnson and Johnson (JNJ), BP p.l.c. ADS (BP), Options, Genzyme (GENZ)

BP (
BP) closed up $1.79 Monday to $38.65. The company reported a $17 billion loss Tuesday morning and announced it has replaced CEO Tony Hayward with Bob Dudley. Overall option implied volatility of 51 is below a level of 78 from June 28, according to Track Data, suggesting decreasing price movement.
Genzyme (
GENZ) closed up $4.86 to $67.38. Sanofi-Aventis (
SNY), GlaxoSmithKline (
GSK) and Johnson & Johnson (
JNJ) may be interested in making a play for GENZ, reports the
Wall Street Journal. Overall option implied volatility of 40 is above GENZ 26-week average of 31, according to Track Data, suggesting larger price movement.
Update is by Stock Specialist Paul Foster of theflyonthewall.com.
Posted Jul 14th 2010 4:00PM by Jon Ogg (RSS feed)
Filed under: Cisco Systems (CSCO), Intel (INTC), Toyota Motor Corp. (TM), BP p.l.c. ADS (BP)

You do not get too many instances where stocks rally for six straight days. This unofficial verdict was up on the day for a seventh day, but this was a sloppy rally today that literally came down to the closing bell. Earnings season got off to a good start, but weak retail data and a
lowered 2010 economic recovery target out of the FOMC Minutes took away the gains that were in place earlier today. The good news is that the fears of a double dip recession seem to have been overdone.
Here were today's unofficial closing bell levels:
Dow 10,366.72 +3.70 (0.04%)
S&P 500 1,095.17 -0.17 (-0.02%)
Nasdaq 2,249.84 +7.81 (0.35%)
Top Analyst CallsContinue reading Closing Bell: A Rally Fizzles (BP, CSCO, GSK, INTC, KBH, NOC, TM)
Posted Jul 1st 2010 5:50PM by Wade Hansen (RSS feed)
Filed under: Stocks to Sell
Short sellers are starting to pile on Forest Laboratories (
FRX), and the drug manufacturer may not be able to sustain the bearish weight. Short interest on Forest has jumped 410.4%, or 14,253,017 shares -- rising from a previous short-interest level of 3,473,213 shares to the current level of 17,726,230 shares -- during the past few weeks.
Based on the average trading volume for Forest, it will take short sellers 4 days to cover their short positions if they wanted to completely reverse their trades. Seeing a jump in short interest like this is a clear indication there is a growing number of traders out there who believe Forest is going to be moving lower in the near future. In fact, it shows they believe it enough to put their money where their mouth is.
Continue reading Short Sellers Piling on Forest Laboratories
Posted Jun 28th 2010 2:30PM by Melly Alazraki (RSS feed)
Filed under: Pfizer (PFE), Novartis AG ADS (NVS), Merck and Co (MRK), Lilly (Eli) (LLY), Stocks to Buy

In its weekend edition,
Barron's Andrew Bary wonders whether
Big Pharma's punishment on Wall Street has gone too far. The sector has fallen out of favor with Wall Street and now has one of the lowest price/
earnings ratios of any major sector of the stock market, Bary writes.
Investors are staying away from the large pharmaceutical companies ahead of their looming patent cliff, when blockbuster drugs like Lipitor, Plavix and Singulair lose patent protection and lose most of the sales from these drugs to generics. Investors also fear the companies don't have enough new drugs in the pipeline to make up for the lost sales, which could mean big hits to earnings.
But when the Street writes off one of the world's most important industries and with valuations at all-time lows, investors ought to take notice, Bary says. Especially when the average dividend yield of the big drugmakers is 4.8%.
Continue reading Wall Street Ignoring Big Pharma -- Should You?
Posted Jun 11th 2010 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Walgreen Co (WAG), Bristol-Myers Squibb (BMY), U.S. Steel (X), Analyst Initiations, Lions Gate Entertainment (LGF)
Analyst Upgrades
- Barclays upgraded GlaxoSmithKline (GSK) to overweight from equal weight and said investor concerns regarding Advair and Avandia are overdone.
- Leerink upgraded Bristol-Myers (BMY) to outperform from market perform, citing management's pipeline execution. Shares were also upgraded at Citigroup this morning to buy from hold.
- Goldman upgraded Medco Health (MHS) to buy from neutral and raised its price target on shares to $76 from $67. The firm cites valuation and expectations that earnings will accelerate in 2H10 driven by a stronger generic outlook.
- U.S. Steel (X) was upgraded to neutral from sell at UBS.
- Blyth (BTH) was upgraded to hold from underperform at Jefferies.
- IPC The Hospitalist Co. (IPCM) was upgraded to buy from hold at Deutsche Bank.
Continue reading Analyst Calls: BMY, FSLR, GSK, LGF, MHS, PVH, SAI, SU, WAG, X ...
Posted Jun 2nd 2010 11:40AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, JPMorgan Chase (JPM), AutoZone Inc (AZO), Carnival Corp (CCL), Analyst Initiations, Deere and Co (DE), Polo Ralph Lauren'A' (RL)
Analyst Upgrades
- UBS upgraded JPMorgan (JPM) to buy from neutral and has a $50 price target on the stock. The firm cites valuation for the upgrade.
- Morgan Joseph upgraded Deere (DE) to buy from hold, citing strong U.S. demand for combines and tractors, favorable fundamentals in Brazil, and expectations for improved domestic construction-equipment demand. The firm has a $75 price target on the stock.
- Wells Fargo upgraded Venoco (VQ) to outperform from market perform to reflect increased confidence in the company's Monterey Shale potential.
- GlaxoSmithKline (GSK) was upgraded to buy from hold at Jefferies.
- Tenet Healthcare (THC) was upgraded to positive from neutral at Susquehanna.
- Agnico-Eagle (AEM) was upgraded to outperform from sector perform at RBC Capital.
Continue reading Analyst Calls: AZO, CCL, CSIQ, DE, GSK, JPM, NILE, RCL, RL, THC, VQ ...
Next Page >